- Kezar Life Sciences reported successful trial for lupus drug.
- KZR stock has spiked more than 90% on Tuesday to trade as high as $11.02.
- KZR share price has found support around $10.14, up 75%.
Kezar Life Sciences (KZR) announced a breakthrough late Monday that today concerning a drug to treat lupus nephritis. Results from the second phase clinical trial evaluating zetomipzomib showed "positive, topline results." Shares of the biotech stock opened up 90% higher at $11.02 but then dropped down nearer $10, still up 75% in the first hour.
Also read: Amazon Stock Deep Dive: AMZN price target at $106 with near-term risks offset by long-term growth
"The MISSION Phase 2 topline results show a clinically meaningful overall renal response to zetomipzomib after 6 months, without high-dose induction therapy. Patients in the trial also experienced reductions in extra-renal manifestations of lupus. Zetomipzomib appears to be immunomodulatory, well-tolerated and steroid-sparing – all important attributes for patients with autoimmune disease who are often young and active," said Noreen R. Henig, M.D., Kezar’s Chief Medical Officer. "Based on the strength of these results, we plan to continue developing zetomipzomib for patients with lupus nephritis, as well as evaluate development opportunities for systemic lupus erythematosus."
The two major achievements pointed to in the study were:
- "11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months"
- "6 of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less at 6 months"
This is quite impressive since the drug had few significant side effects. Lupus affects about 1.5 million people in the US and about 5 million globally, according to the Lupus Foundation of America. About 90% of cases are found in women. When Lupus attacks the kidneys, it is called lupus nephritis.
Kezar Life Sciences stock forecast
Right away the chart tells us KZR stock is in an uptrend. The 9-day moving average has advanced above the 21-day and not just because of Tuesday's massive spike. It seems that a slow, drawn out uptrend began with the range low on June 13. The Moving Average Convergence Divergence (MACD) has been trending in the right direction with the MACD line leading the signal line.
KZR share price now needs to close the gap created on May 4. To do so, it needs to crawl up to $11.65, the low from May 2. Watch how KZR trends and where it finds a base of support on Tuesday and Wednesday. it may take a week before another rally is sustained. Support is at $6.
KZR 1-day chart
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD stabilizes near 1.0800 as trading action turns subdued
EUR/USD holds steady near 1.0800 on Thursday and remains on track to end the day in negative territory following upbeat macroeconomic data releases from the US. The action in financial markets turn subdued as trading volumes thin out heading into Easter holiday.
GBP/USD extends sideways grind above 1.2600
GBP/USD fluctuates in a narrow channel above 1.2600 on Thursday. The better-than-expected Initial Jobless Claims data from the US and the upward revision to the Q4 GDP growth help the USD stay resilient against its rivals and limits the pair's upside.
Gold pulls away from daily highs, holds above $2,200
Gold retreats from daily highs but holds comfortably above $2,200 in the American session on Thursday. The benchmark 10-year US Treasury bond yield stays near 4.2% after upbeat US data and makes it difficult for XAU/USD to gather further bullish momentum.
XRP price falls to $0.60 support as Ripple ruling doesn’t help Coinbase lawsuit against SEC
XRP programmatic sales ruling by Judge Torres was completely rejected by another US Court that ruled in favor of the SEC in a lawsuit against Coinbase.
Portfolio rebalancing and reflation trades emerge into Q2
Yesterday’s price action pointed at a possible end-of-quarter portfolio rebalancing as the session saw the laggards of the quarter like Apple and Tesla gain, and the stars like Microsoft and Nvidia retreat.